NASDAQ · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Envoy Medical, Inc. COCH
5 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$241,000
▲ 7.1% vs FY2024
EPS · FY25
$-1.23
Dividend / sh · FY25
—
Payout · FY25
-8%
ROE · FY25
—
Net margin · FY25
-9857.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 241,000.00
Revenue, FY2025 · full 5-year series below
Revenue
Net income
The company lost 9857 cents on every revenue dollar this year.
Per share
USD -1.23
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-9240.7%
Net margin-9857.3%
Return on assets-236.4%
Returned to shareholders
USD 1.8M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 1.8M
Net buybacks—
Share of profit-7.7%
Consecutive raises—
USD 1.8M in dividends went back to shareholders in a year without profit.
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+0.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 8.6M
total assets, end of FY2025
Total assetsUSD 8.6M
EquityUSD -12.2M
CashUSD 3.7M
Current ratio0.54×
Equity funds -142% of total assets.
History
5 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
Revenue $B
0.0
0.0
0.0
0.0
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
·
Income tax $B
·
·
·
0.0
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.23
−1.49
−2.54
−1.57
·
Dividend / sh $
·
·
·
·
·
Payout %
−8
−12
·
·
·
ROE %
·
·
·
·
·
Shares out B
·
·
0.02
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
14 of 14
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed